37 However, no difference in survival has been observed in BRCA1/2 carriers treated with other systemic therapies (chemotherapy, abiraterone, and enzalutamide).38,39 The evidence to support the role of BRCA1/2 in prostate cancer is strong enough to include genetic testing among individuals who meet National Comprehensive Cancer Network guidelines based upon reported family history and/or clinical characteristics. This evidence concerns the gene BRCA1 and prostate cancer.